20.02.27 / News
MAQS has advised IRLAB Therapeutics in connection with two share issues
MAQS Advokatbyrå has advised IRLAB Therapeutics in connection with a directed issue with proceeds amounting to approx. SEK 70 million as well as an over subscribed rights issue with proceeds amounting to approx. SEK 145 million.
The directed issue, which took place in December 2019, was subscribed for by a number of institutional and qualified investors after an accelerated book building process. The rights issue took place in February 2020.
IRLAB Therapeutics is a research and development company, listed on Nasdaq First North Premier Growth Market, focused on the development of novel therapies for the treatment of neurodegenerative diseases, in particular Parkinson’s disease and dementia.
MAQS team consisted mainly of Dag Fredlund, Eric Ehrencrona, Henrik Nordling and Hanna Friberg.